The Australian medical diagnostic company Healius Ltd. has entered into an agreement with Affinity Equity Partners to sell the Lumus Imaging division for 965 million Australian dollars ($657 million). This is reported in the Healius press release.
The deal is aimed at optimizing assets, which will allow us to focus on business development in the field of pathology and reduce pressure on the company's balance sheet due to losses.
The deal is subject to approval by the Australian regulator.
UBS Securities Australia Ltd. is acting as financial advisor to Healius, and Herbert Smith Freehills is acting as legal advisor.
Healius offers a wide range of medical services and technological solutions in the field of healthcare and performs the functions of a day surgery operator. Healius deals with the problems of diagnostics, medical technologies, pathologies, IVF centers, etc. The company operates medical and pathology centers in Australia (Agilex Biolabs, Dorevitch Pathology and IQ Pathology services). The headquarters is located in St. Leonards (South Wales, Australia).
Affinity Equity Partners is one of the largest specialized Asian private equity companies in the leveraged buyout and growth capital transactions sector. Affinity is present in Korea, Southeast Asia, China, Australia and New Zealand. The headquarters is located in Hong Kong.
Read also in our Telegram channel "Mergers and acquisitions. AK&M».
